Beam Therapeutics BEAM Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's net gains (losses) on investments?
- Beam Therapeutics (BEAM) reported net gains (losses) on investments of $16K in Q1 2026.
- How has Beam Therapeutics's net gains (losses) on investments changed year-over-year?
- Beam Therapeutics's net gains (losses) on investments increased by 100.8% year-over-year, from -$2.08M to $16K.
- What is the long-term trend for Beam Therapeutics's net gains (losses) on investments?
- Over 2 years (2022 to 2024), Beam Therapeutics's net gains (losses) on investments has grown at a -16.5% compound annual growth rate (CAGR), from $20.2M to -$14.09M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.